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The present randomised phase II study was an effort to evaluate single-agent gemcitabine as a first-line systemic treatment of Asian
patients with unresectable hepatocellular carcinoma (HCC). Gemcitabine was given via intravenous infusion at 1250mgm
 2 on days
1 and 8 of 3-week cycles. Patients were randomised to receive gemcitabine as a 30-min intravenous infusion (standard schedule) or
at a fixed dose rate (FDR) of 10mgm
 2min
 1. A total of 50 patients were enrolled in the study, of whom 48 received study therapy.
One patient on standard schedule had a partial response, for an overall response rate of 2.1% (95% CI: 0.05–11.1%). The median
time to progression and survival time were 46 and 97 days, respectively. The overall rates of Grade 3 or 4 haematological and
nonhaematological toxicities were 39.6 and 64.6%, respectively, with no significant difference between the two treatment arms.
There were no drug-related deaths and severe clinical toxicities were rare. Both schedules of gemcitabine were safe and toxicity was
well manageable in this patient population. However, gemcitabine seems no more active than other cytotoxic agents when used
alone for systemic treatment of advanced HCC.
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Hepatocellular carcinoma (HCC) is a major cause of cancer death,
in Asia and worldwide (Pisani et al, 1999). Most patients have
inoperable disease at the time of diagnosis and need systemic
therapy at some point of their disease. No systemic therapy has
shown reproducible benefit in controlled clinical trials and
treatment outcome has remained poor (Venook, 1994; Simonetti
et al, 1997; Fong et al, 2001).
The antimetabolite gemcitabine (GEMZAR
s) is a deoxycytidine
analogue (20,20-difluorodeoxycytidine, dFdC) that inhibits DNA
synthesis (Plunkett et al, 1989). Preclinical studies of gemcitabine
have shown promising activity in a human HCC model (Graziadei
et al, 1998). A phase II study of single-agent gemcitabine in
advanced HCC in Taiwan found a response rate of 17.8% and good
tolerance (Yang et al, 2000). In that study, gemcitabine was given
as an intravenous infusion over 30min, which is the standard
mode of gemcitabine administration. Preclinical and clinical
studies have found that the intracellular accumulation of dFdC
triphosphate, the active moiety of gemcitabine incorporated into
DNA, gets saturated at gemcitabine levels of 15–20mmoll
 1 and
can be maximised by the administration of gemcitabine at a fixed
dose rate (FDR) of 10mgm
 2min
 1 (Grunewald et al, 1990, 1991;
Abbruzzese et al, 1991; Tempero et al, 1999). In two phase I
studies, the maximum tolerated dose of gemcitabine at FDR was
found to be 1500mgm
 2 (Brand et al, 1997) and 1800mgm
 2
(Touroutoglou et al, 1998). Both studies suggested a phase II
starting dose of 1500mgm
 2. The toxicity profile of FDR
gemcitabine was similar to that of the standard schedule, with
granulocytopaenia and thrombocytopaenia the dose-limiting
toxicities (Brand et al, 1997; Touroutoglou et al, 1998). A
randomised phase II study in pancreatic cancer has suggested
that FDR gemcitabine may produce higher efficacy than standard
schedule (Tempero et al, 1999). The present multinational
randomised phase II study was an effort to confirm the previously
observed activity of standard schedule gemcitabine in Asian
patients with unresectable HCC and to evaluate the activity and
toxicity of FDR gemcitabine in this patient population.
PATIENTS AND METHODS
Eligible patients had a tissue diagnosis of HCC or serum alpha-
fetoprotein of at least 400ngl
 1 plus liver imaging studies that
were considered highly suggestive of HCC. Patients had to have
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ldistant metastases (stage IV) or locally advanced disease (stage
IIIB) not eligible for curative surgery, and bidimensionally
measurable disease. Prior systemic chemotherapy was not allowed.
Intra-arterial chemotherapy was allowed if given more than 3
months prior to enrolment and not including more than one
cytotoxic drug. Other inclusion criteria included: Karnofsky
performance status (KPS) of 70 or higher and estimated life
expectancy of at least 12 weeks; age of at least 18 years and no
higher than 75 years; white blood cell count X3.0 10
9l
 1,
absolute neutrophil count (ANC) X2.0 10
9l
 1, platelets
X75 10
9l
 1, haemoglobin X9.0gdl
 1; total serum bilirubin
p4 upper limit of normal (ULN), ALT and AST p4 ULN, and
serum albumin X20gl
 1; serum creatinine p1.5 ULN; Okuda
stage I or II (Okuda et al, 1985); and lastly, written informed
consent. Exclusion criteria included: central nervous system
metastases; any other concomitant tumour therapy; pregnancy or
breastfeeding; active infection, active peptic ulcer, active cardiac
disease requiring therapy, unstable diabetes mellitus; other
documented malignancy except treated nonmelanoma skin cancer,
carcinoma in situ of the cervix, or other cancers diagnosed at least
5 years previously and without recurrence. The study was
conducted according to ICH Good Clinical Practice Guidelines,
including obtaining informed consent from all patients.
A minimisation randomisation process (Pocock, 1983) was used
in which patients were stratified on stage of disease (Okuda I or II),
KPS (70–80 or 90–100) and whether they had prior intra-arterial
chemotherapy (yes or no). A block size of 4 was used when there
was balance between the prognostic factors and a ratio of 3:2 with
a block size of 5 was used if there was imbalance. In both arms,
gemcitabine was given at 1250mgm
 2 as an intravenous infusion
on days 1 and 8 of 3-weekly cycles. In the standard schedule arm,
gemcitabine was administered over 30min, in the FDR arm at
10mgm
 2min
 1 (eg, over 125min for a dose of 1250mgm
 2). An
infusion pump was used to ensure exact infusion time. Antiemetics
were used according to the standard local practice.
To start a next cycle, ANC had to be X1.0 10
9l
 1, platelets
X75 10
9l
 1, AST, ALT and serum bilirubin p4 ULN, and
patients had to have no other toxicity of common toxicity criteria
(CTC) Grade 3 or 4 with the exception of nausea, vomiting and
anaemia. The dose of gemcitabine was reduced by 20% in a
subsequent cycle in the case of ANC o0.5 10
9l
 1 associated with
fever (defined as a single episode of X38.51C or three episodes of
X38.51C during a 24-h period or lasting more than 7 days),
platelet count o25 10
9l
 1 or o50 10
9l
 1 associated with
bleeding, or AST, ALT or serum bilirubin 44 ULN at any time
during the preceding cycle. If any other toxicity of CTC Grade 3 or
4 occurred during the preceding cycle, with the exception of
nausea, vomiting and anaemia, the dose of gemcitabine could be
reduced by 20% at the discretion of the investigator. The day 8
dose of gemcitabine was omitted in case of ANC o0.5 10
9l
 1,
platelets o50 10
9l
 1, AST, ALT or serum bilirubin 44 ULN,
or any other toxicity of CTC Grade 3 or 4 with the exception of
nausea, vomiting and anaemia. Prophylactic use of granulocyte
colony-stimulating factor (G-CSF) or granulocyte–macrophage
colony-stimulating factor (GM-CSF) was not allowed in this study.
Therapeutic CSF was permitted in case of febrile neutropaenia.
Before study enrolment, patients were required to have a
physical examination, chest X-ray, abdominal and chest computed
tomography, complete blood work-up and ECG. Abdominal
ultrasound and bone X-ray and/or scan were optional as clinically
indicated. Before the start of each cycle and day 8 dosing of
gemcitabine, a physical examination, full blood count and blood
work-up were performed. A full blood count was obtained around
day 15. Upon discontinuation of study therapy, survival status was
assessed until 12 months past randomisation or death, whichever
occurred first. If patients had an objective remission or stable
disease at the time of discontinuation of study therapy, response
status was evaluated every 2 months.
Tumour response status was evaluated every two cycles.
Confirmation of response was required at no earlier than 4 weeks.
Complete response was defined as complete disappearance of all
known disease; partial response as at least 50% reduction in the
size of measurable lesions; no change as less than 50% reduction
and 25% increase in the size of measurable lesions; and progressive
disease as equal to or more than 25% increase in the size of at least
one measurable lesion or any appearance of a new lesion. Duration
of response and stable disease, and time to progression were
measured from the date of randomisation to documented disease
progression. Survival time was calculated from the date of
randomisation to the date of death or last follow-up. Toxicity
was graded according to the National Cancer Institute Common
Toxicity Criteria, version 2.0 (National Cancer Institute, 1999).
The primary objective of this study was to evaluate the response
rate of either treatment. One of the secondary objectives was to
select the gemcitabine schedule with the higher therapeutic ratio
(ie, activity vs toxicity) for further study in advanced HCC. Based
on the data from Taiwan (Yang et al, 2000), a minimum response
rate of 10% was assumed for either arm. The Simon design for
randomised phase II studies was applied to select a treatment
regimen for further investigation (Simon et al, 1985). Assuming a
mean true response rate of 10%, and the true response rate
achieved by one treatment to be 10% higher, a total sample size of
56 patients gave a probability of higher than 0.85 such that the
better of the two treatments will have the higher observed response
rate. Kaplan–Meier statistics were used to estimate time-to-event
measures and log rank test was used for comparisons of treatment
groups. Toxicity of the two arms was compared using Fisher’s
exact test.
RESULTS
In total, 50 patients were entered on trial. Two patients did not
receive study therapy because they did not meet the eligibility
criteria. In all, 25 and 23 patients received gemcitabine at standard
schedule and FDR, respectively. Patient enrolment was stopped
early. Two reports of no activity by single-agent gemcitabine in
advanced HCC (Kubicka et al, 2001; Ulrich-Pur et al, 2001)
prompted an unplanned interim analysis, which found one partial
response in 42 patients evaluable for response assessment. This
level of activity was considered too low to warrant further patient
enrolment.
All data reported here are based on the 48 patients who received
study therapy. Of these, 26 patients were enrolled in the People’s
Republic of China, 15 in Thailand, six in South Korea and one in
Hong Kong. The two treatment groups were well balanced for
major baseline characteristics (Table 1). There were 43 male and
five female patients. In all, 12 patients had a tissue diagnosis of
HCC, and in 36 patients the diagnosis was based on elevation of
serum alpha-fetoprotein of higher than 400ngml
 1 plus liver
imaging studies considered as highly suggestive of HCC.
Efficacy
No patient in the FDR arm and one patient in the standard
schedule arm had an objective partial response, for an overall
response rate of 2.1% (1 out of 48 patients; 95% CI: 0.05–11.1%).
The response rates for the standard schedule and FDR arm were
4% (1 out of 25 patients; 95% CI: 0.1–20.4%) and 0% (0 out of 23
patients; 95% CI: 0–14.8%), respectively. The duration of the
single partial response was 29.7 weeks. In total, 26 patients (54%)
had progressive disease as best response. The time to progression
and median survival time were 46 (95% CI: 43–57) and 97 (95%
CI: 71–143) days, respectively, with no statistical differences
between the two arms (Figures 1 and 2). Five patients (11.6%) were
alive at 1 year.
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In the standard schedule arm, the rates of Grade 3/4 haematolo-
gical and nonhaematological toxicities were 44.0 and 76.0%,
respectively. The corresponding rates in the FDR arm were 34.8
and 52.2%, respectively, with no statistical difference between the
two treatment arms. Individual Grade 3/4 toxicities are listed in
Table 2. There were no drug-related deaths. Six patients (12.5%)
received G-CSF in 8 out of 113 treatment cycles (7.1%). The
number of cycles administered was 73 in the standard schedule
and 40 in the FDR arm. The mean number of cycles per patient for
the entire study population was 2.35, with a range of 1–6. Five
patients completed six cycles of study therapy, all on the standard
schedule arm. There were no signs of cumulative toxicity. The
most common cause of early discontinuation was disease
progression. Dose adjustments in subsequent cycles and on day
8 occurred in four (3.5%) and 36 (32%) cycles, respectively. With a
planned dose intensity of 833mgm
 2week
 1 the actual dose
intensity achieved was 703.4mgm
 2week
 1, for a relative dose
intensity of 0.844. There was no significant difference in dose
intensity between the two arms.
DISCUSSION
Hepatocellular carcinoma is known to be highly resistant to
chemotherapy (Fong et al, 2001). Doxorubicin is widely considered
the most active single-agent, but more recent studies have failed to
demonstrate meaningful activity (Lai et al, 1988, 1989; Mok et al,
1999). Newer agents such as raltitrexed, paclitaxel, irinotecan,
nolatrexed and eniluracil-5-fluorouracil have shown no activity
(Rougier et al, 1997; Chao et al, 1998; Mok et al, 1999; Stuart et al,
1999; Llovet et al, 2001; O’Reilly et al, 2001).
Table 1 Patient and tumour characteristics
Standard schedule
(n¼25)
FDR
(n¼23)
Age (years)
Median 48.7 49.0
Range 35.2–70.3 31.8–66.7
KPS
Median 80 80
Range 70–100 70–90
Stage
IIIB 4 2
IV 21 21
Two or more organ sites involved 5 12
Okuda stage
I1 2 9
II 13 14
Prior therapy
None 22 20
Surgery 1 2
IACE 1 1
IAE 1 0
History of chronic benign liver disease
None 6 9
Chronic hepatitis 12 9
Liver cirrhosis 7 5
Hepatitis B serology
Positive 18 21
Negative 3 0
Unknown 4 2
Hepatitis C serology
Positive 5 1
Negative 7 11
Unknown 13 11
IACE¼intra-arterial chemo-embolisation; IAE¼intra-arterial embolisation.
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Figure 1 Time to progression by treatment arm.
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Figure 2 Survival by treatment arm.
Table 2 Grade 3 and 4 toxicities
Standard schedule (n¼25) FDR (n¼23)
34 3 4
Leukopaenia 2 0 3 0
Neutropaenia 4 1 2 2
Thrombocytopaenia 4 0 1 0
Anaemia 4 0 3 1
Febrile neutropaenia 0 0 0 0
Infection 0 0 1 0
Bleeding 3 1 0 0
AST/ALT 8 0 4 0
GGT 7 0 5 0
Bilirubin 1 0 2 0
Nausea 0 0 0 0
Vomiting 0 0 1 0
Skin rash/desquamation 1 0 0 0
Fatigue 3 0 1 1
Gemcitabine in hepatocellular carcinoma
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agent gemcitabine. Preliminary data in advanced pancreatic cancer
(Tempero et al, 1999) led us to hypothesise that gemcitabine
administered at FDR may achieve higher activity in HCC.
However, no objective remission was obtained in the FDR arm
of this study. A phase II study of single-agent gemcitabine in
Taiwan found a response rate of 17.8% in 28 patients with
advanced HCC (Yang et al, 2000). More recently, three studies in
Europe and the US have shown no activity (Kubicka et al, 2001;
Ulrich-Pur et al, 2001; Fuchs et al, 2002). This discrepancy may
suggest differing sensitivity of HCC in Asia vs Western countries.
However, the present trial was conducted in three Asian countries
and was not able to reproduce the activity reported from Taiwan.
The eligibility criteria in the current and Taiwan trial were similar,
and so were the reported characteristics of the study patients.
However, the median survival in the Taiwan study was 18.7 weeks,
while it was 13.9 weeks (97 days) in the present study. This
suggests more favourable prognostic features of the patients in the
Taiwan study, which may also have increased the probability of
tumour response. However, the median survival in the US study
was 6.9 months and no objective response was observed (Fuchs
et al, 2002). The median survival of 97 days in the current trial is
similar to the 3.1 months found for HCC patients classified as
intermediate-risk by the Chinese University Prognostic Index
(CUPI) (Leung et al, 2002). We performed a retrospective risk
classification of the study patients according to the CUPI and
found 19 (39.6%) and 28 (58.3%) patients falling in the
intermediate- and low-risk categories, respectively. The mean
CUPI for the overall population was þ1.33 (range,  4t oþ9),
which is close to the lower CUPI cutoff value of þ2 for
intermediate risk (Leung et al, 2002). Accordingly, the survival
outcome in the present study seems to be consistent with the Hong
Kong study (Leung et al, 2002).
Gemcitabine was used at full dose, yet toxicity was well
manageable, with a low rate of Grade 3 or 4 clinical toxicities,
low need for G-CSF, and no drug-related deaths. The relative dose
intensity was 0.844. All other studies of gemcitabine in HCC, used
as single agent or in combination with cisplatin or doxorubicin,
have shown mild to modest toxicity (Babu et al, 2000; Yang et al,
2000, 2002; Kubicka et al, 2001; Ulrich-Pur et al, 2001; Fuchs et al,
2002). We anticipated higher toxicity for FDR gemcitabine, as has
been previously observed (Brand et al, 1997; Tempero et al, 1999).
Interestingly, this was not the case. As is common in HCC, many
patients in this study had underlying benign chronic liver disease.
In Asia, this is typically the result of hepatitis B infection, as was
the case in the present study. Of note, no hepatitis flare was
observed.
In conclusion, both schedules of gemcitabine were found to be
safe and toxicity was well manageable in this patient population,
but gemcitabine seems no more active than other cytotoxic agents
when used alone for systemic treatment of advanced HCC.
ACKNOWLEDGEMENTS
We thank Wendy Leung and Joanne Renold for project manage-
ment, Justine Southby for medical writing support, and Drs O-Tur
Saeseow (Khon Kaen University, Khon Kaen, Thailand) and
Benjamin CY Wong (The University of Hong Kong, Queen Mary
Hospital, Hong Kong, SAR China) for study participation.
REFERENCES
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B,
Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical,
plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:
491–498
Babu G, Parikh P, Fuloria J, Doval D, Prabhakaran P, Pai VR, Vaid A,
Nguyen B, Kapil S (2000) A multicenter phase II trial of gemcitabine and
cisplatin in unresectable hepatocellular carcinoma. Ann Oncol 11(Suppl
4): 269P (abstract)
Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly
gemcitabine administered as a prolonged infusion in patients with
pancreatic cancer and other solid tumors. Invest N Drugs 15: 331–341
Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M,
Whang-Peng J, Chi KH, Lui WY, Lee SD (1998) Phase II and
pharmacokinetic study of paclitaxel therapy for unresectable hepatocel-
lular carcinoma patients. Br J Cancer 78: 34–39
Fong Y, Kemeny N, Lawrence T (2001) Cancer of the liver and biliary
tree. In Cancer: Principles and Practice of Oncology, DeVita V,
Hellman S, Rosenberg S (eds) pp 1162–1203. Philadelphia, PA: JB
Lippincott
Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M,
Mayer RJ, Stuart KE (2002) A phase II trial of gemcitabine in patients
with advanced hepatocellular carcinoma. Cancer 94: 3186–3191
Graziadei I, Kelly T, Schirmer M, Geisen FH, Vogel W, Kowalinka G (1998)
Antitumor effect of the nucleoside analogs 2-chlordeoxyadenosine and
20,20-difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol
28: 504–509
Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of
20,20-difluorodeoxycytidine 50-triphosphate accumulation by mononuc-
lear cells during a phase I trial of gemcitabine. Cancer Chemother
Pharmacol 27: 258–262
Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P,
Plunkett W (1990) Pharmacologically directed design of the dose rate
and schedule of 20,20-difluorodeoxycytidine (gemcitabine) administra-
tion in leukemia. Cancer Res 50: 6823–6826
Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M (2001) Phase II
study of systemic gemcitabine chemotherapy for advanced unresectable
hepatobiliary carcinomas. Hepatogastroenterology 48: 783–789
Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin versus no
antitumor therapy in inoperable hepatocellular carcinoma. A prospective
randomized trial. Cancer 62: 479–483
Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, Lau JY, Chung HT, Ng MM, Yeoh
EK, Arnold M (1989) Recombinant alpha 2 interferon is superior to
doxorubicin for inoperable hepatocellular carcinoma: a prospective
randomised trial. Br J Cancer 60: 928–933
Leung TWT, Tang AMY, Zee B, Yu SCH, Lai PBS, Lau WY, Johnson PJ
(2002) Factors predicting response and survival in 149 patients with
unresectable hepatocellular carcinoma treated by combination cisplatin,
interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer
94: 421–427
Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I,
Peachey M (2001) A phase II trial of oral eniluracil/5-fluorouracil in
patients with inoperable hepatocellular carcinoma. Eur J Cancer 37:
1352–1358
Mok TSK, Leung TWT, Lee S-D, Chao Y, Chan ATC, Huang A, Lui M-C,
Yeo W, Chak K, Johnston A, Johnson P (1999) A multi-centre
randomized phase II study of nolatrexed versus doxorubicin in
treatment of Chinese patients with advanced hepatocellular carcinoma.
Cancer Chemother Pharmacol 44: 307–311
National Cancer Institute (1999), National Cancer Institute Common
Toxicity Criteria (version 2), Bethesda, MD: Division of Cancer
Treatment and Diagnosis, National Cancer Institute Http://ctep.info.
nih.gov/ctc3/ctc.htm
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H,
Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular
carcinoma and prognosis in relation to treatment. Study of 850 patients.
Cancer 56: 918–928
O’Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM,
Raeburn L, Kemeny NE, Kelsen DP, Saltz LB (2001) A phase II study of
irinotecan in patients with advanced hepatocellular carcinoma. Cancer
91: 101–105
Pisani P, Parkin DM, Bray FI, Ferlay J (1999) Estimates of the world-wide
mortality from twenty-five major cancers in 1990. Int J Cancer 83: 18–29
Plunkett W, Gandhi V, Chubb S, Novak B, Heinemann V, Mineishi S, Sen A,
Herter L, Grindey GB (1989) 20,20-Difluorodeoxycytidine metabolism and
Gemcitabine in hepatocellular carcinoma
Z Guan et al
1868
British Journal of Cancer (2003) 89(10), 1865–1869 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lmechanism of action in human leukemia cells. Nucleosides Nucleotides 8:
775–785
Pocock SJ (1983) Clinical Trials: A Practical Approach. Chichester: John
Wiley & Sons
Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis A, Seymour L
(1997) A phase II study of raltitrexed (‘Tomudex’) in patients with
hepatocellular carcinoma. Ann Oncol 8: 500–502
Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical
trials. Cancer Treat Rep 69: 1375–1381
Simonetti RG, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of
hepatocellular carcinoma: a systematic review of randomized controlled
trials. Ann Oncol 8: 117–136
Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A (1999) A phase II
trial of nolatrexed dihydrochloride in patients with advanced hepatocel-
lular carcinoma. Cancer 86: 410–414
Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H,
Lenzi R, Abbruzzese J (1999) Randomized phase II trial of dose intense
gemcitabine by standard infusion vs fixed dose rate in metastatic
pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18: 1048 (abstract)
Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL
(1998) Clinical results of a pharmacodynamically based strategy for
higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:
1003–1008
Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B Raderer M, Scheithauer W
(2001) Treatment of advanced hepatocellular carcinoma with biweekly
high-dose gemcitabine. Oncology 60: 313–315
Venook AP (1994) Treatment of hepatocellular carcinoma: too many
options? J Clin Oncol 12: 1323–1334
Yang T-S, Lin Y-C, Chen J-S, Wang H-M, Wang C-H (2000) Phase II study
of gemcitabine in patients with advanced hepatocellular carcinoma.
Cancer 89: 750–756
Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC (2002) Gemcitabine and
doxorubicin for the treatment of patients with advanced hepatocellular
carcinoma: a phase I–II trial. Ann Oncol 13: 1771–1778
Gemcitabine in hepatocellular carcinoma
Z Guan et al
1869
British Journal of Cancer (2003) 89(10), 1865–1869 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l